tiprankstipranks
Genscript Biotech (GNNSF)
OTHER OTC:GNNSF
US Market
GNNSF
Genscript Biotech
RESEARCH TOOLSreports

Genscript Biotech (GNNSF) Stock Forecast & Price Target

19 Followers
See the Price Targets and Ratings of:

GNNSF Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Genscript
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GNNSF Stock 12 Month Forecast

Average Price Target

$3.10
▲(54.82% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Genscript Biotech in the last 3 months. The average price target is $3.10 with a high forecast of $3.26 and a low forecast of $2.93. The average price target represents a 54.82% change from the last price of $2.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.2602005700000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.096361785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.932523,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.0969385053846152,2.193877010769231,2.290815516153846,2.387754021538462,2.484692526923077,2.5816310323076923,2.678569537692308,2.7755080430769232,2.8724465484615385,2.969385053846154,3.0663235592307694,3.1632620646153846,{"y":3.2602005700000003,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.084335521923077,2.168671043846154,2.2530065657692306,2.3373420876923077,2.4216776096153847,2.5060131315384617,2.5903486534615388,2.6746841753846153,2.7590196973076924,2.8433552192307694,2.927690741153846,3.0120262630769234,{"y":3.096361785,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.0717325384615384,2.1434650769230768,2.2151976153846156,2.286930153846154,2.3586626923076923,2.4303952307692307,2.5021277692307695,2.573860307692308,2.6455928461538463,2.7173253846153846,2.789057923076923,2.8607904615384614,{"y":2.932523,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.291,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.665,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.475,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3.26Average Price Target$3.10Lowest Price Target$2.93
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GNNSF
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$2.93
Buy
46.63%
Upside
Reiterated
08/03/26
J.P. Morgan Sticks to Its Buy Rating for Genscript Biotech (GNNSF)
Guotai Haitong Analyst forecast on GNNSF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$3.26
Buy
63.01%
Upside
Reiterated
05/13/26
Genscript Biotech (GNNSF) Gets a Buy from Guotai Haitong
Jefferies Analyst forecast on GNNSF
Cui Cui
Jefferies
Jefferies
$1.98
Buy
-1.19%
Downside
Reiterated
04/03/26
Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
CICC Analyst forecast on GNNSF
Unknown Analyst
CICC
Not Ranked
CICC
$2.28
Buy
14.11%
Upside
Reiterated
03/18/26
Genscript Biotech (GNNSF) Receives a Buy from CICC
Huatai Securities Analyst forecast on GNNSF
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$2.07
Buy
3.66%
Upside
Reiterated
03/17/26
Huatai Securities Sticks to Its Buy Rating for Genscript Biotech (GNNSF)
Morgan Stanley Analyst forecast on GNNSF
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$2.79
Buy
39.61%
Upside
Reiterated
10/16/25
Citic Securities Analyst forecast on GNNSF
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$2.93
Buy
46.63%
Upside
Reiterated
08/22/25
Daiwa Analyst forecast on GNNSF
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$3.32
Buy
65.75%
Upside
Reiterated
08/18/25
BOCOM International Holdings Company Analyst forecast on GNNSF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$3.67
Buy
83.28%
Upside
Reiterated
08/18/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GNNSF
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$2.93
Buy
46.63%
Upside
Reiterated
08/03/26
J.P. Morgan Sticks to Its Buy Rating for Genscript Biotech (GNNSF)
Guotai Haitong Analyst forecast on GNNSF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$3.26
Buy
63.01%
Upside
Reiterated
05/13/26
Genscript Biotech (GNNSF) Gets a Buy from Guotai Haitong
Jefferies Analyst forecast on GNNSF
Cui Cui
Jefferies
Jefferies
$1.98
Buy
-1.19%
Downside
Reiterated
04/03/26
Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
CICC Analyst forecast on GNNSF
Unknown Analyst
CICC
Not Ranked
CICC
$2.28
Buy
14.11%
Upside
Reiterated
03/18/26
Genscript Biotech (GNNSF) Receives a Buy from CICC
Huatai Securities Analyst forecast on GNNSF
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$2.07
Buy
3.66%
Upside
Reiterated
03/17/26
Huatai Securities Sticks to Its Buy Rating for Genscript Biotech (GNNSF)
Morgan Stanley Analyst forecast on GNNSF
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$2.79
Buy
39.61%
Upside
Reiterated
10/16/25
Citic Securities Analyst forecast on GNNSF
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$2.93
Buy
46.63%
Upside
Reiterated
08/22/25
Daiwa Analyst forecast on GNNSF
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$3.32
Buy
65.75%
Upside
Reiterated
08/18/25
BOCOM International Holdings Company Analyst forecast on GNNSF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$3.67
Buy
83.28%
Upside
Reiterated
08/18/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genscript Biotech

3 Months
Yang HuangJ.P. Morgan
Success Rate
2/2 ratings generated profit
100%
Average Return
+3.45%
Copying Yang Huang's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +3.45% per trade.
1 Year
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
1/2 ratings generated profit
50%
Average Return
+10.70%
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.70% per trade.
2 Years
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
1/2 ratings generated profit
50%
Average Return
+10.70%
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +10.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GNNSF Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
3
1
1
0
Buy
2
2
1
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
5
2
1
1
In the current month, GNNSF has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GNNSF average Analyst price target in the past 3 months is 3.10.
Each month's total comprises the sum of three months' worth of ratings.

GNNSF Financial Forecast

GNNSF Earnings Forecast

Next quarter’s earnings estimate for GNNSF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s EPS was -$0.23. GNNSF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.
Next quarter’s earnings estimate for GNNSF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s EPS was -$0.23. GNNSF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.

GNNSF Sales Forecast

Next quarter’s sales forecast for GNNSF is $383.94M with a range of $383.94M to $383.94M. The previous quarter’s sales results were $438.29M. GNNSF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.
Next quarter’s sales forecast for GNNSF is $383.94M with a range of $383.94M to $383.94M. The previous quarter’s sales results were $438.29M. GNNSF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.

GNNSF Stock Forecast FAQ

What is GNNSF’s average 12-month price target, according to analysts?
Based on analyst ratings, Genscript Biotech’s 12-month average price target is 3.10.
    What is GNNSF’s upside potential, based on the analysts’ average price target?
    Genscript Biotech has 54.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GNNSF a Buy, Sell or Hold?
          Genscript Biotech has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Genscript Biotech’s price target?
            The average price target for Genscript Biotech is 3.10. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $3.26 ,the lowest forecast is $2.93. The average price target represents 54.82% Increase from the current price of $2.
              What do analysts say about Genscript Biotech?
              Genscript Biotech’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of GNNSF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.